LONDON (Reuters) - An experimental drug for severe sepsis from AstraZeneca and BTG failed to help patients in a mid-stage clinical trial and its development will now be halted, BTG said on Wednesday. BTG expects to take a charge of approximately 28 million pounds ($43.82 million) in the current financial year related to the failure of AZD9773, or CytoFab. ($1 = 0.6390 British pounds) (Reporting by Ben Hirschler) via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment